Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Breast Cancer

 

Premenopausal Early Assessment; ER+, HER2-, FLT (7536a)
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01928186

Vaccine Therapy for HER2+ Stage IV Breast Cancer
Phase II Study to Evaluate the Development of HER2/neu (HER2)-Specific Memory T Cells After HER2 Peptide-Based Vaccination in Patients with Advanced Stage HER2+ Breast Cancer

Investigator: Lupe Salazar, MD;   Conditions: Breast Cancer;    Status: Closed;   Study ID: NCT01729884

Postmenopausal Early Assessment; ER+, HER2-, FLT (7536b)
Imaging Early Response of ER+, HER2- Breast Cancer To Aromatase Inhibitor (AI) +/- Ovarian Suppression (OS) Therapy With [18F]Fluorothymidine (FLT) PET

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01928186

Pertuzumab in Combination With Herceptin and Vinorelbine for Metastatic or HER2-Positive Breast Cancer (UW12012)
A Two-cohort, Open-label, Multicenter Phase II Trial Assessing the Efficacy and Safety of Pertuzumab Given in Combination With Trastuzumab and Vinorelbine in First Line Patients With HER2-positive Advanced (Metastatic or Locally Advanced) Breast Cancer.

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Temporarily On Hold;   Study ID: NCT01565083

Targeted Therapies for Triple Negative Advanced Breast Cancer (6628)
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel (Abraxane) and Bevacizumab (Avastin) Followed by Maintenance Targeted Therapy With Bevacizumab (Avastin) and Erlotinib (Tarceva)

Investigator: Jennifer Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT00733408

Monitoring Patients with Triple Negative Breast Cancer (8132)
Intensive Trial of OMics in Cancer (ITOMIC) 001- Intensive Longitudinal Monitoring in Patients with Triple Negative Breast Cancer

Investigator: Tony Blau, MD;   Conditions: Breast Cancer; Solid Tumors;    Status: Recruiting;   Study ID: NCT01957514

I-SPY2 Trial (7518)
I-SPY2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and moLecular Analysis 2)

Investigator: Larissa Korde;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01042379

Vaccine Therapy and Trastuzumab w/wo Polysaccharide-K (PSKĀ®) for Stage IV HER2 Positive Breast Cancer
Phase I/II Randomized Study of Combination Immunotherapy With or Without Polysaccharide Krestin (PSKĀ®) Concurrently With a HER2 ICD Peptide-Based Vaccine and Trastuzumab in Patients With Stage IV Breast Cancer

Investigator: Lupe G. Salazar, MD;   Conditions: HER2-positive Breast Cancer;    Status: Recruiting;   Study ID: NCT01922921

Psychoeducation for Spouses of Women With Breast Cancer
Psychoeducation for Spouses of Women With Breast Cancer (Helping Her Heal)

Investigator: ;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01723943

SPORE Project 3 (7587)
Quantitative Dynamic PET and MRI and Breast Cancer Therapy

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01931709

TDM1 Platelet (7900)
Thrombokinetic Studies of Trastuzumab Emtansine

Investigator: V.K. Gadi, MD, PhD;   Conditions: Breast Cancer;    Status: Pending;   Study ID: NCT01816035

Eribulin Mesylate for Previously Treated Metastatic Breast Cancer (8093)
Phase II Trial of Metronomic Eribulin (Halaven) In Pretreated Metastatic Breast Cancer (MBC)

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01908101

SGN-LIV1A for Breast Cancer (13038)
A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01969643

Tissue Collection for ER and Her2 Diagnoses for Patients with Metastatic Breast Cancer (8085)
Quantification of ER and Her2 in Bone Biopsy using a Multiple-Immuno-MRM assay in Metastatic Breast Cancer

Investigator: Julie R. Gralow, MD;   Conditions: Metastatic Breast Cancer;    Status: Recruiting

MPDL3280A + Cobimetinib for Locally Advanced or Metastatic Cancer
A Phase 1b Study of the Safety and Pharmacology of MPDL3280A Administered With Cobimetinib in Patients With Locally Advanced or Metastatic Solid Tumors

Investigator: Laura Chow, MD;   Conditions: Neoplasms;    Status: Recruiting;   Study ID: NCT01988896

MSB0010718C for Metastatic or Locally Advanced Solid Tumors
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications

Investigator: Mary (Nora) L. Disis, MD;   Conditions: Breast Cancer, Solid Tumors;    Status: Recruiting;   Study ID: NCT01772004

Hormone Therapy w/o Everolimus for Breast Cancer (SWOG 1207)
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

Investigator: Julie R. Gralow, MD;   Conditions: Breast Cancer;    Status: Recruiting;   Study ID: NCT01674140

Pertuzumab + Trastuzumab as Neoadjuvant Treatment for HER2-Positive Breast Cancer (TBCRC 026)
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer

Investigator: Jennifer M. Specht, MD;   Conditions: Breast Cancer;    Status: Pending;   Study ID: NCT01937117

FDG PET (7159)
FDG PET (Reproducibility Across Centers)

Investigator: Hannah M. Linden, MD;   Conditions: Breast Cancer;    Status: Recruiting